This review highlights targets, such as LILRB4, SEMA4A, ITGB7, CD70, and CCR1. These candidates demonstrate the potential to address key challenges in MM treatment, including antigen escape, treatment resistance, and off-tumor toxicity. This evidence concerns the gene CCR1 and Miyoshi myopathy.